ELOXX PHARMACEUTICALS, INC. (ELOX) Debt Components
- 2026-06-30: Long-term Debt, Current MaturitiesUSD (m); Long-term Debt, Excluding Current MaturitiesUSD (m); Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD (m).
- 2026-06-30: Long-term Debt, Current MaturitiesUSD $0.00; Long-term Debt, Excluding Current MaturitiesUSD (m); Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD (m).
- 2026-03-31: Long-term Debt, Current MaturitiesUSD (m); Long-term Debt, Excluding Current MaturitiesUSD (m); Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD (m).
- 2026-03-31: Long-term Debt, Current MaturitiesUSD $0.00; Long-term Debt, Excluding Current MaturitiesUSD (m); Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD (m).
ELOXX PHARMACEUTICALS, INC. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt, Current Maturities USD | Long-term Debt, Excluding Current Maturities USD | Long-term Debt USD | Long-Term Debt, Maturity, Year One USD | Line of Credit Facility, Increase, Accrued Interest USD | Long-term Debt, Gross USD | Debt Instrument, Increase, Accrued Interest USD | Debt Instrument, Unamortized Discount USD | Notes Payable, Current USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Year Five USD | Long-Term Debt, Maturity, Remainder of Fiscal Year USD | Line of Credit Facility, Maximum Borrowing Capacity USD | Line of Credit Facility, Interest Rate at Period End pure | Debt Instrument, Periodic Payment USD | Debt Instrument, Convertible, Beneficial Conversion Feature USD | Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate pure | Line of Credit Facility, Amount Outstanding (Deprecated 2014-01-31) USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | 6 month · $56.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-06-30 | $0.00 | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · $56.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $0.00 | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-02-26 | (m) | (m) | (m) | (m) | $1.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $1.13M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $1.00M | $0.00 | $1.00M | $1.00M | (m) | $1.00M | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $6.52M | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $2.22M | $1.61M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $2.82M | $2.62M | $4.62M | $681.00K | (m) | $4.78M | (m) | $159.00K | (m) | $2.99M | $1.11M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $2.28M | $3.33M | $4.79M | $906.00K | (m) | $5.00M | (m) | $209.00K | (m) | $2.99M | $1.11M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $1.54M | $4.03M | $4.74M | $2.99M | (m) | $5.00M | (m) | $256.00K | (m) | $1.11M | (m) | (m) | (m) | $906.00K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $3.98M | $8.56M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 13.75% | (m) |
| 2022-12-31 | (m) | (m) | $11.72M | $4.20M | (m) | $12.50M | (m) | $782.00K | (m) | $6.10M | $2.19M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $2.53M | $9.86M | $11.57M | $4.20M | (m) | $12.50M | (m) | $926.00K | (m) | $6.10M | $2.19M | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $1.12M | $11.13M | $11.44M | $4.20M | (m) | $12.50M | (m) | $1.06M | (m) | $6.10M | $2.19M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $12.12M | $11.30M | $4.20M | (m) | $12.50M | (m) | $1.20M | (m) | $6.10M | $2.19M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $0.00 | $12.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | $11.18M | (m) | (m) | $12.50M | (m) | $1.32M | (m) | $4.20M | $6.10M | $2.19M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $11.91M | $11.09M | (m) | (m) | $12.50M | (m) | $1.41M | (m) | $4.20M | $6.10M | $2.19M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $5.69M | $3.64M | $8.42M | $5.40M | (m) | $8.71M | (m) | $290.00K | (m) | $417.00K | (m) | (m) | (m) | $2.90M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $5.56M | $4.91M | $9.57M | $5.40M | (m) | $9.96M | (m) | $388.00K | (m) | $417.00K | (m) | (m) | (m) | $4.15M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $5.24M | $6.38M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | $10.71M | $5.40M | (m) | $11.21M | (m) | $498.00K | (m) | $5.40M | $417.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $4.92M | $7.82M | $11.84M | $5.40M | (m) | $12.46M | (m) | $623.00K | (m) | $5.40M | $417.00K | (m) | (m) | $1.25M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $5.15M | $8.70M | $12.95M | (m) | (m) | $13.71M | (m) | $761.00K | (m) | $5.53M | $5.18M | $417.00K | (m) | $2.59M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $4.77M | $9.38M | $13.26M | (m) | (m) | $14.17M | (m) | $910.00K | (m) | $5.00M | $5.00M | $417.00K | (m) | $3.75M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $4.34M | $10.50M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | $13.94M | $4.58M | (m) | $15.00M | (m) | $1.06M | (m) | $5.00M | $5.00M | $417.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $3.49M | $11.19M | $13.78M | (m) | (m) | $15.00M | (m) | $1.22M | (m) | $4.58M | $5.00M | $5.00M | $417.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $2.23M | $12.31M | $13.64M | (m) | (m) | $15.00M | (m) | $1.36M | (m) | $4.58M | $5.00M | $5.00M | $417.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $984.00K | $13.41M | $17.87M | (m) | (m) | (m) | (m) | $1.51M | (m) | $5.62M | $5.66M | $5.25M | $420.00K | $917.00K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · $1.00M | (m) | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $712.34K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $407.12K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $589.07K | $256.82K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $300.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $2.19M |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $2.19M |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $2.19M |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $5.33M | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $2.19M |
| 2012-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $2.20M |
| 2012-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $2.20M |
| 2012-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $2.20M |
| 2012-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $5.33M | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $2.20M |
| 2010-02-17 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $3.00M | (m) | (m) | (m) | (m) | (m) |
| 2010-02-17 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3.75% | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Tevogen Inc. (TVGN) | United States | $0.049B |